Semaglutide started in old age added 92 days to female mice's median lifespan
A Berkeley group ran the drug against a matched 24 percent food cut and found it equalled dieting on strength and coordination while beating it on memory and glucose. The lifespan race between the two is still running.
The Scientist · Science desk
What happened
- Daily semaglutide injections begun in 20-month-old female mice and continued for life raised median survival from 742 days in saline controls to 834 days, a gain of about 12 percent.
- A separate five-month arm pitted the drug against mice fed 24 percent less food, matching the cut semaglutide produced through appetite suppression, and the two ended level on muscle strength and coordination.
- Nir Barzilai of the Albert Einstein College of Medicine, who was not involved, told Scientific American the study cannot say whether dieting or the drug extends life more, and that the missing data bothers him.
Why it matters
- What's now possible capability A geroscience candidate with approved indications in diabetes, obesity, cardiovascular risk, kidney decline and fatty liver disease can be trialled for ageing endpoints without first building a safety file for a new molecule.
- Who has to decide decision Anyone treating this as evidence that a GLP-1 beats dieting for longevity is committing ahead of the experiment that would settle it, which is still in progress in Chen's laboratory.
- What it limits constraint Because the drug and diet arms were matched on a 24 percent intake cut, the design can isolate what is not attributable to eating less, but it cannot rank the two on survival, so the mimetic label stays provisional.
- What it sets up precedent Spatial memory, exploratory drive and glucose trajectories now set the bar for what a serious follow-up has to measure, which is a harder endpoint list than weight or HbA1c.
Next story · Science · 5h ago
Baker lab's from-scratch zinc proteases cut their chosen target in 36% of 135 designsConfirmed2 publishers
That 12 percent carries a large constant in its denominator. Injections began at 20 months, about 600 days of life already spent, and the saline controls reached a median of 742 days [2][1]. So the untreated animals had roughly 142 days of median life remaining when treatment started, and the treated ones about 234: a gain nearer 65 percent of remaining life than 12 percent of total life [17]. Use a 30.4-day month for the start point and it comes out at 69 percent [17]. Both framings are honest, they answer different questions, and the survival-curve number is the conservative one.
The most useful piece of the design is the matched-intake arm. Semaglutide cut food intake by 24 percent, and the comparison group was simply fed 24 percent less for five months [14][4]. That subtraction is what licenses any claim about effects independent of eating less. On muscle strength and coordination the two arms landed together [4]. On exploratory drive, spatial memory and glucose control the drug ran ahead, and the Nature abstract reports improvements above the animals' own baselines rather than a slower decline [10]. Why the drug has that edge is unresolved; Chen's answer is that they do not know yet [7].
The housekeeping measurements point the same way. After adjusting for body weight, locomotor activity, respiratory exchange ratio, oxygen consumption, carbon dioxide production and energy expenditure were not significantly changed [14], so the visible lever is intake rather than burn rate. The behavioural gains, including maze solving and rotarod balance, survived adjustment for the treated animals being leaner [5]. Liver gene activity overlapped substantially with published calorie-restriction data, with inflammation and fat processing damped and glucose-handling and protein-maintenance genes raised in both [6].
The thing this does not tell you is which intervention wins on survival. The paper does not rank dieting against the drug, and Nir Barzilai of the Albert Einstein College of Medicine, who was not involved, told Scientific American the data is not there and it bugs him [12]. Chen says that experiment is running now [13]. It also does not tell you about males: the cohort was female C57BL/6 mice, one sex in one strain in one laboratory [9].
What makes this more than another mouse geroprotector is the drug's existing paperwork. Semaglutide is approved for type 2 diabetes and obesity, for lowering cardiovascular risk, for slowing kidney decline and for fatty liver disease, with trial data accumulating in sleep apnea and osteoarthritis [8]. Chen's stated motivation was that nobody could explain why one molecule helps so many unrelated conditions [8]. A calorie-restriction mimetic is one explanation [11], and it is the kind of explanation that generates human trials quickly, because the molecule, the dosing and the safety file already exist. A mouse survival curve is not a longevity indication, and the arm that would test the mimetic claim head to head has not reported [13].
What to watch
- Chen's running head-to-head lifespan comparison of semaglutide against calorie restriction, and which survival curve comes out ahead.
- Replication in male mice and in strains other than C57BL/6, ideally across more than one laboratory.
- Whether any human trial adopts a GLP-1 arm with functional ageing endpoints rather than weight or glycaemic ones.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence74
- Adoption28
- Hype gap+16
- Incentives42
- Confidence68
Perspective Coverage
3 publishers- Builder
- Builder 44%
- Operator
- Operator 33%
- Investor
- Investor 23%
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Female mice injected with semaglutide starting at 20 months of age and continuing for the rest of their lives had median lifespan rise about 12 percent, from 742 days to 834 days, against a same-age comparison group that ate freely and received saline injections.
- [2]
Treatment began in mice 20 months old, described in the report as roughly equivalent to a woman in her 60s, and injections continued for the remainder of the animals' lives.
- [3]
The study was published in Nature; the senior author is Danica Chen, a longevity researcher at the University of California, Berkeley, who has studied calorie restriction for two decades.
- [4]
In a separate five-month experiment, one group of late-life mice received semaglutide while another was fed 24 percent less food, about the same reduction the treated mice made through appetite suppression; semaglutide matched the diet on measures of muscle strength and coordination.
- [5]
Semaglutide-treated mice explored more, balanced longer on a rotating rod, ran farther on a treadmill and solved a maze faster, and those gains held after the researchers accounted for the animals being leaner than their peers; their tissues were less worn out and inflamed.
- [6]
The team sequenced gene activity in the livers of treated mice and compared it with existing calorie-restriction data; the overlap was significant, with both interventions quieting inflammation and fat processing and increasing genes for handling blood sugar and maintaining proteins.
- [7]
The semaglutide mice had better memory scores, curiosity levels and blood sugar than the calorie-restricted mice; Chen said 'In that sense, it's more than just a calorie restriction' and, asked why the drug has this edge, said 'The short answer is: we don't know yet.'
- [8]
Beyond diabetes and obesity, semaglutide is approved to lower cardiovascular risk, slow kidney decline and treat fatty liver disease, with trial data accumulating for sleep apnea and osteoarthritis; Chen said the scientific community had no answer for why one drug benefits so many diseases.
- [9]
The cohort was 20-month-old female C57BL/6 mice treated daily by subcutaneous injection with vehicle or semaglutide; three months of treatment improved physiological function, attenuated hallmarks of ageing and modulated nutrient sensors and conserved genetic regulators of ageing, and continued treatment extended lifespan.
- [10]
In a longitudinal study in direct comparison with matched calorie restriction, semaglutide preserved baseline function and recapitulated many functional benefits of calorie restriction while also producing improvements above baseline and more favourable trajectories than calorie restriction in exploratory drive, spatial memory and glucose control.
- [11]
The authors note that sustained calorie restriction is difficult to practise and that there is a need for calorie-restriction mimetics suitable for human application, and hypothesised that GLP-1 medicines might act as such a mimetic.
- [12]
Nir Barzilai, a longevity researcher at the Albert Einstein College of Medicine who was not involved in the study, said the study does not answer whether dieting or semaglutide extends lifespan more: 'Maybe calorie restriction increases the lifespan more? The data is not there, and it bugs me.'
- [13]
Chen said the experiment directly comparing lifespan under semaglutide and under calorie restriction is currently ongoing, and that she does not predict what the results will be.
- [14]
Semaglutide treatment reduced food intake by 24 percent but did not significantly alter locomotor activity, respiratory exchange ratio, oxygen consumption, carbon dioxide production or energy expenditure after ANCOVA adjustment using body weight as a covariate.
- [15]
Control mice maintained body weight after 20 months of age, there was no body-weight difference between groups before treatment, and semaglutide treatment reduced body weight and tissue weight.
- [16]
The reported medians imply an absolute gain of 92 days and a proportional gain of 12.4 percent.
- [17]
Measured from the start of treatment at 20 months rather than from birth, median remaining life rose from about 142 days to about 234 days, roughly 65 percent, or from 134 to 226 days, roughly 69 percent, depending on whether a 30-day or 30.4-day month is used.
Sources
3 independent publishers whose own reporting we read for this story.
- genengnews.comGLP-1 Drug Semaglutide Slows Aging and Extends Lifespan in Mice
1 article · September 2, 2026
- nature.comLate-life semaglutide treatment slows ageing and extends lifespan in female mice
1 article · September 1, 2026
- scientificamerican.comGLP-1 weight-loss medication could slow aging and extend lifespan
1 article · September 2, 2026
Topics and entities
Topics
- Ageing biology and lifespan studies
- Preclinical Translation
- Calorie-restriction mimetics
- GLP-1 drugs and longevity
Entities
- SLIM LIVER trial
- Semaglutide
- Albert Einstein College of Medicine
- University of California, Berkeley
- Nature
- National Institute on Aging